Dementia with Lewy bodies (DLB) is the second commonest cause of degenerative dementia in older people, responsible for 10-15% of all cases. In addition, dementia develops in up to 80% of people with Parkinson's disease, often known as Parkinson's disease dementia (PDD). PDD and DLB are commonly grouped together as Lewy body dementia (LBD) because they share many clinical features, have similar underlying neurobiology and respond to similar management approaches. LBD affects around 160,000 people in the UK and, like other dementias, prevalence will approximately double over the next 30 years.
Whilst diagnostic criteria for Alzheimer’s disease (AD) have been reasonably well developed over the last 30 years, those for LBD have only relatively recently been described and validated. As such, they are not yet optimally applied in routine clinical practice and because of this LBD remains under-detected in clinical practice, even in specialist secondary care NHS settings. There are several reasons for this:
1) Key symptoms of LBD such as hallucinations, fluctuation and parkinsonism are often not properly assessed in memory and dementia services;
2) There remains a lack of general knowledge regarding the clinical features and management of LBD in comparison to the other two main causes of dementia, AD and vascular dementia (VaD);
3) In neurology and geriatric medicine services, where most people with Parkinson's disease are seen, there is a lack of awareness of cognitive symptoms so diagnosis of dementia is either not made or delayed.
Because of the scale of the problem and the number of LBD cases not appropriately recognised and managed, there is a need for improved methods for case detection, and clear evidence-based guidelines for management. Optimal management of LBD is important because such subjects often receive antipsychotic medication for psychiatric and behavioural symptoms, yet these are contra-indicated because of a potentially fatal sensitivity reaction (in addition to the other well-known risks of antipsychotics in those with dementia). Parkinsonism is often inadequately treated in DLB, though treatments can sometimes be effective providing they are started in low dose and titrated carefully. Sleep disturbance, falls, associated depression and autonomic dysfunction are other key features of LBD which are uncommon in other dementias, yet have effective and specific management options available that can significantly improve quality of life for patient and carer.
By developing, validating and implementing the assessment and management toolkits for LBD in both dementia assessment services and neurology services, we will significantly impact on improving diagnosis of LBD and patient management, with direct benefit to patients. The assessment and management toolkits are copyrighted but are free to use and available to download from this site, please see under the relevant tabs. We aim to update them regularly and the latest versions will always be available here. Please see the publications section for further details regarding their development and use. A version of the management toolkit has been developed for use in the US by the Lewy Body Dementia Association (LBDA) and is available via their website: https://lbda.org/diamond-lewy
The DIAMOND-Lewy programme has been funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (DTC-RP-PG-0311-12001).
The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
Information for patients and carers
Lewy body dementia is the second most common type of dementia, however it is difficult to diagnose. The purpose of this programme is to develop a simple assessment tool to be used in memory clinics and movement disorder/ neurology clinics in order to improve the rates of diagnosis of dementia with Lewy bodies and Parkinson's disease dementia, so that appropriate treatment can be started as soon as possible. We have also developed a standardised guide to management of the illness so that people who have Lewy body dementia receive the same level of care wherever they live.
The study teams at Newcastle and Cambridge are not able to provide support or advice for people affected by dementia or movement disorders. For help with these queries and for further support we recommend contacting the Lewy Body Society, the Alzheimer's Society (dedicated helpline 0333 150 3456or visit their website below for other contact options), or Parkinson's UK; please click on the links below to go to their individual websites, or for people who live outside the UK please contact equivalents in other countries.
The Lewy Body Society is the only UK charity dedicated to supporting people with Lewy body dementia.
Contacts